chevron_leftBack
As of 13 June 2026, TWi Biotechnology, Inc. has a market cap of $110.42M USD, ranking #24839 globally and #1317 in Taiwan.
It ranks #2222 in the Healthcare sector, and #803 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$110.42MUSD
3.49B TWD
Enterprise Value
$99.96MUSD
3.16B TWD
EBITDA (TTM)
-$4.66MUSD
-147.28M TWD
Net Income (TTM)
-$4.92MUSD
-155.28M TWD
PB Ratio
13.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Chen-En Tsai
open_in_new
Employees
23
Founded
2010
Website
twibiotech.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.1% | 39% | 64% | 56% | -6.5% | 177% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
6610
安成生物科技股份有限公司
ISIN: TW0006610009
Shares Out.:
Shares Outstanding:
205.579M1
Shares Float:
55.354M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
32.05 TWD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About TWi Biotechnology, Inc.
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseases. It has a drug development agreement with Hong Kong Winhealth Pharma Group Co., Limited. in Mainland China, Hong Kong, and Macao markets. TWi Biotechnology, Inc. was founded in 2010 and is based in Taipei, Taiwan.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
TWSE: 6446
|
$7.77B
7K%
245.34B TWD
|
48.6
|
|
TWSE: 1795
|
$1.83B
2K%
57.95B TWD
|
12.2
|
|
TPEX: 4123
|
$921.9M
735%
29.11B TWD
|
3.4
|
|
TPEX: 6535
|
$806.11M
630%
25.46B TWD
|
-
|
|
TPEX: 4743
|
$786.01M
612%
24.82B TWD
|
-
|
|
TPEX: 4105
|
$581.84M
427%
18.38B TWD
|
11.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
690K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
496K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
327K%
|
97.4
|
|
SIX: RO
|
$321.52B
291K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
261K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
249K%
218.9B CHF
|
20.5
|
chevron_leftBack